Literature DB >> 26754357

Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.

Colin D Godwin1, Megan Othus2, Morgan A Powell3, Sarah A Buckley1, Elihu H Estey3,4, Roland B Walter3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26754357      PMCID： PMC5003083          DOI： 10.3109/10428194.2015.1135436

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  12 in total

1.  Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.

Authors:  Mark Levis; Farhad Ravandi; Eunice S Wang; Maria R Baer; Alexander Perl; Steven Coutre; Harry Erba; Robert K Stuart; Michele Baccarani; Larry D Cripe; Martin S Tallman; Giovanna Meloni; Lucy A Godley; Amelia A Langston; Sergio Amadori; Ian D Lewis; Arnon Nagler; Richard Stone; Karen Yee; Anjali Advani; Dan Douer; W Wiktor-Jedrzejczak; Gunnar Juliusson; Mark R Litzow; Stephen Petersdorf; Miguel Sanz; Hagop M Kantarjian; Takashi Sato; Lothar Tremmel; Debra M Bensen-Kennedy; Donald Small; B Douglas Smith
Journal:  Blood       Date:  2011-01-26       Impact factor: 22.113

2.  The development and validation of two prediction models to identify employees at risk of high sickness absence.

Authors:  Corné A Roelen; Willem van Rhenen; Johan W Groothoff; Jac J van der Klink; Ute Bültmann; Martijn W Heymans
Journal:  Eur J Public Health       Date:  2012-04-25       Impact factor: 3.367

3.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

4.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.

Authors:  Roland B Walter; Megan Othus; Gautam Borthakur; Farhad Ravandi; Jorge E Cortes; Sherry A Pierce; Frederick R Appelbaum; Hagop A Kantarjian; Elihu H Estey
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

5.  Age and acute myeloid leukemia.

Authors:  Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

6.  Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.

Authors:  M Othus; H Kantarjian; S Petersdorf; F Ravandi; J Godwin; J Cortes; S Pierce; H Erba; S Faderl; F R Appelbaum; E Estey
Journal:  Leukemia       Date:  2013-06-13       Impact factor: 11.528

7.  Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Authors:  Farhad Ravandi; Ellen K Ritchie; Hamid Sayar; Jeffrey E Lancet; Michael D Craig; Norbert Vey; Stephen A Strickland; Gary J Schiller; Elias Jabbour; Harry P Erba; Arnaud Pigneux; Heinz-August Horst; Christian Recher; Virginia M Klimek; Jorge Cortes; Gail J Roboz; Olatoyosi Odenike; Xavier Thomas; Violaine Havelange; Johan Maertens; Hans-Günter Derigs; Michael Heuser; Lloyd Damon; Bayard L Powell; Gianluca Gaidano; Angelo-Michele Carella; Andrew Wei; Donna Hogge; Adam R Craig; Judith A Fox; Renee Ward; Jennifer A Smith; Gary Acton; Cyrus Mehta; Robert K Stuart; Hagop M Kantarjian
Journal:  Lancet Oncol       Date:  2015-07-30       Impact factor: 41.316

8.  Quantitative analysis of the color change after iodine staining for diagnosing esophageal high-grade intraepithelial neoplasia and invasive cancer.

Authors:  Ryu Ishihara; Takuya Yamada; Hiroyasu Iishi; Motohiko Kato; Shunsuke Yamamoto; Sachiko Yamamoto; Eriko Masuda; Koichi Tatsumi; Yoji Takeuchi; Koji Higashino; Noriya Uedo; Masaharu Tatsuta; Shingo Ishiguro
Journal:  Gastrointest Endosc       Date:  2008-08-20       Impact factor: 9.427

9.  Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.

Authors:  R B Walter; M Othus; E M Paietta; J Racevskis; H F Fernandez; J-W Lee; Z Sun; M S Tallman; J Patel; M Gönen; O Abdel-Wahab; R L Levine; E H Estey
Journal:  Leukemia       Date:  2015-03-16       Impact factor: 11.528

10.  Can routine laboratory tests discriminate between severe acute respiratory syndrome and other causes of community-acquired pneumonia?

Authors:  Matthew P Muller; George Tomlinson; Thomas J Marrie; Patrick Tang; Allison McGeer; Donald E Low; Allan S Detsky; Wayne L Gold
Journal:  Clin Infect Dis       Date:  2005-03-16       Impact factor: 9.079
View more
  1 in total

1.  Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.

Authors:  Anna B Halpern; Megan Othus; Emily M Huebner; Bart L Scott; Paul C Hendrie; Mary-Elizabeth M Percival; Pamela S Becker; Heather A Smith; Vivian G Oehler; Johnnie J Orozco; Ryan D Cassaday; Kelda M Gardner; Tara L Chen; Sarah A Buckley; Kaysey F Orlowski; Asma Anwar; Elihu H Estey; Roland B Walter
Journal:  Haematologica       Date:  2018-11-08       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.